NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. NeuroBo is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity.

Our strategic partner and the largest investor, Dong-A ST Co. Ltd., is part of Dong-A Socio Group of companies established in 1932 and based in South Korea. NeuroBo Pharmaceuticals has the full support of Dong-A ST’s R&D Research center, providing the company with access to R&D, scientific and CMC expertise.

DA-1241 is a once-daily, oral, novel G-protein-coupled receptor 119 (GPR119) agonist currently a Phase 2a clinical trial in MASH.

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR,) for once-a-week injection. NeuroBo has FDA, IND clearance to initiate a Phase 1 clinical trial for the treatment of obesity, which is expected to begin during the first half of 2024.